-
1 . Academic Journal
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
- 저자
- by Mills, Anthony M; Rizzardini, Giuliano; Ramgopal, Moti N; Osiyemi, Olayemi O; Bogner, Johannes R, et al.
- 소스
- In The Lancet HIV June 2024 11(6):e357-e368
-
-
7 . Academic Journal
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
- 저자
- by Ramgopal, Moti N; Castagna, Antonella; Cazanave, Charles; Diaz-Brito, Vicens; Dretler, Robin, et al.
- 소스
- In The Lancet HIV September 2023 10(9):e566-e577
-
7 . Academic Journal
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- 저자
- by Wohl, David A; Yazdanpanah, Yazdan; Baumgarten, Axel; Clarke, Amanda; Thompson, Melanie A, et al.
- 소스
- In The Lancet HIV June 2019 6(6):e355-e363
-
-